Cargando…

581. Risks versus Benefits of Metronidazole Use for the Prevention of Acute GVHD in Allogeneic Stem Cell Transplant Recipients

BACKGROUND: Currently, acute graft versus host disease (aGVHD) prophylaxis in hematopoietic stem cell transplants (HSCT) varies amongst different institutions. There is a lack of data supporting the use of metronidazole for aGVHD prophylaxis in HSCT. To further investigate if metronidazole has an ef...

Descripción completa

Detalles Bibliográficos
Autores principales:	Young, Mary T, Monogue, Marguerite, Patel, Hetalkumari
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776744/ http://dx.doi.org/10.1093/ofid/ofaa439.775

Ejemplares similares

1096. Linezolid versus Tedizolid for the Treatment of Nontuberculous Mycobacteria in Solid Organ Transplant Recipients: An Assessment of Safety
por: Poon, Yi Kee, et al.
Publicado: (2020)

1083. Clinical Efficacy of Tedizolid for the Treatment of Mycobacterium abscessus complex Infections in Solid Organ Transplant Recipients
por: Poon, Yi Kee, et al.
Publicado: (2020)

Pretransplant CSF-1 therapy expands recipient macrophages and ameliorates GVHD after allogeneic hematopoietic cell transplantation
por: Hashimoto, Daigo, et al.
Publicado: (2011)

A61 PRE-ALLOGENIC STEM CELL TRANSPLANT CLINICAL FACTORS AND THEIR ASSOCIATION WITH CHRONIC GRAFT VERSUS HOST DISEASE - A RISK FACTOR ANALYSIS FOR CHRONIC GVHD PREDICTION
por: Alajmi, A, et al.
Publicado: (2022)

The Effect of Granulocyte Colony-Stimulating Factor (G-CSF) on Early Complications and Graft-Versus-Host Disease (GVHD) in Allogeneic Stem Cell Transplantation (ASCT) Recipients
por: Aydın Kaynar, Lale, et al.
Publicado: (2023)

Bone Marrow GvHD after Allogeneic Hematopoietic Stem Cell Transplantation
por: Szyska, Martin, et al.
Publicado: (2016)

Effects of aGVHD and cGVHD on Survival Rate in Patients with Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation
por: Shokouhi, Shabnam, et al.
Publicado: (2015)

P1329: POST-TRANSPLANT CYCLOPHOSPHAMIDE (PT-CY) VERSUS ANTITHYMOCYTE GLOBULIN (ATG) AS GVHD PROPHYLAXIS FOR MATCHED UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION.
por: Dachy, F., et al.
Publicado: (2022)

Feasibility of conditioning with thymoglobulin and reduced intensity TBI to reduce acute GVHD in recipients of allogeneic SCT
por: Toor, A, et al.
Publicado: (2008)

Lower incidence of chronic GVHD observed after transplantation with cryopreserved unrelated allogeneic stem cells
por: Maurer, Katie, et al.
Publicado: (2023)

Novel insights into GVHD and immune reconstitution after allogeneic hematopoietic cell transplantation
por: Teshima, Takanori, et al.
Publicado: (2023)

Results of Multicenter Phase II Study With Imatinib Mesylate in Allogeneic Recipients With Steroid-Refractory Chronic GVHD
por: Baek, Dong Won, et al.
Publicado: (2022)

P581: A MARKOV DECISION ANALYSIS OF AZACITIDINE AND VENETOCLAX VERSUS INDUCTION CHEMOTHERAPY FOR THE TREATMENT OF MEDICALLY-FIT PATIENTS WITH ACUTE MYELOID LEUKEMIA
por: Ravindran, Mithunan, et al.
Publicado: (2023)

581. COVID-19 Vaccine Perceptions in Adults from Greater Nashville Tennessee
por: Fernandez, Kailee N, et al.
Publicado: (2021)

1315. Ceftaroline Versus Vancomycin for the Treatment of Acute Pulmonary Exacerbations of Cystic Fibrosis in Adults
por: Esquivel, Marc, et al.
Publicado: (2021)

Colon biopsies for evaluation of acute graft-versus-host disease (A-GVHD) in allogeneic bone marrow transplant patients
por: Shidham, Vinod B, et al.
Publicado: (2003)

Relation between Acute GVHD and NK Cell Subset Reconstitution Following Allogeneic Stem Cell Transplantation
por: Ullrich, Evelyn, et al.
Publicado: (2016)

Coordinated responses of natural anticoagulants to allogeneic stem cell transplantation and acute GVHD – A longitudinal study
por: Przybyla, Beata, et al.
Publicado: (2017)

Donor‐derived M2 macrophages attenuate GVHD after allogeneic hematopoietic stem cell transplantation
por: Hanaki, Ryo, et al.
Publicado: (2021)

PB2338: QUALITY OF LIFE AFTER ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION: IMPACT OF CHRONIC GVHD
por: Belloumi, D., et al.
Publicado: (2022)

Defibrotide impact on the acute GVHD disease incidence in pediatric hematopoietic stem cell transplant recipients
por: Squillaci, Domenica, et al.
Publicado: (2023)

A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant
por: Ramalingam, Sendhilnathan, et al.
Publicado: (2021)

Interleukin-6 as Biomarker for Acute GvHD and Survival After Allogeneic Transplant With Post-transplant Cyclophosphamide
por: Greco, Raffaella, et al.
Publicado: (2019)

P1613: SINGLE-CELL ANALYSIS FOLLOWING SARS-COV-2 MRNA VACCINE IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS
por: Tranter, E., et al.
Publicado: (2022)

Tedizolid vs Linezolid for the Treatment of Nontuberculous Mycobacteria Infections in Solid Organ Transplant Recipients
por: Poon, Yi Kee, et al.
Publicado: (2021)

581 Chronic Urticaria and Infections
por: Aguilar, Nadia, et al.
Publicado: (2012)

A Preliminary Investigation towards the Risk Stratification of Allogeneic Stem Cell Recipients with Respect to the Potential for Development of GVHD via Their Pre-Transplant Plasma Lipid and Metabolic Signature
por: Contaifer, Daniel, et al.
Publicado: (2019)

Editorial on Translational Research in Graft-Versus-Host Disease (GVHD) and Graft-Versus-Tumor (GVT) Effect After Allogeneic Hematopoietic Cell Transplantation
por: Czech, Marie, et al.
Publicado: (2022)

P1290: UPFRONT ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION CAN PROVIDE SURVIVAL BENEFIT VERSUS HYPOMETHYLATING AGENT IN MYELODYSPLASTIC SYNDROME WITH INCREASED BLASTS I (MDS-IBI)
por: Runzhi, MA, et al.
Publicado: (2023)

Donor γδT Cells Promote GVL Effect and Mitigate aGVHD in Allogeneic Hematopoietic Stem Cell Transplantation
por: Song, Yuan, et al.
Publicado: (2020)

Humoral Responses and Chronic GVHD Exacerbation after COVID-19 Vaccination Post Allogeneic Stem Cell Transplantation
por: Pabst, Caroline, et al.
Publicado: (2022)

P1396: EFFICACY AND SAFETY COMPARISON OF CALCINEURIN INHIBITORS USED FOR GVHD PROPHYLAXIS IN HEMATOPOIETIC STEM CELL TRANSPLANTATION IN CHILDREN WITH THALASSEMIA
por: Zhumatayev, S., et al.
Publicado: (2022)

Serum proteomic profiling and haptoglobin polymorphisms in patients with GVHD after allogeneic hematopoietic cell transplantation
por: McGuirk, Joseph, et al.
Publicado: (2009)

Intestinal Microbiota Influence Immune Tolerance Post Allogeneic Hematopoietic Cell Transplantation and Intestinal GVHD
por: Köhler, Natalie, et al.
Publicado: (2019)

P1526: THE RISK OF DEVELOPING PNEUMOCYSTIS JIROVECII PNEUMONIA PERSISTS EVEN AFTER COMPLETION OF IMMUNOSUPPRESSANTS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION RECIPIENTS
por: Ara, Takahide, et al.
Publicado: (2023)

195. Economic and Clinical Burden of Respiratory Virus Infections in Allogeneic Hematopoietic Cell Transplantation Recipients
por: Ison, Michael G, et al.
Publicado: (2020)

The Trend of Respiratory Virus Infection in Allogeneic Bone Marrow Transplant Recipients during the COVID Pandemic
por: Kaleka, Guneet, et al.
Publicado: (2022)

P1324: A RISK-BASED STRATEGY FOR THE USE OF LETERMOVIR IN CMV-POSITIVE RECIPIENTS OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION
por: Beauvais, D., et al.
Publicado: (2022)

Murine Cytomegalovirus Immediate-Early 1 Gene Expression Correlates with Increased GVHD after Allogeneic Hematopoietic Cell Transplantation in Recipients Reactivating from Latent Infection
por: Palaniyandi, Senthilnathan, et al.
Publicado: (2013)

P1357: IMPAIRED CELLULAR RESPONSES AGAINST SARS-COV-2 AFTER COVID-19 INFECTION IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS
por: Mamez, A.-C., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fd59akuqik32elj9nade0vm0lm